Waterborne antidepressants may affect fish far more than expected

Antidepressants rank among the most widely prescribed classes of drugs in the world, and their journey does not end when a patient swallows a pill. A substantial fraction of these compounds and their metabolic byproducts pass through the body unchanged, exit via wastewater, survive conventional treatment plants, and ultimately accumulate in rivers, lakes, and coastal seas. Once there, they encounter organisms whose brains run on precisely the same chemical currency that these drugs were designed to modulate: serotonin, dopamine, and norepinephrine. A new study from researchers at Tokyo University of Science and Kochi University, published in Environmental Science & Technology, now provides the most detailed molecular picture yet of just how vulnerable fish may be to these omnipresent pollutants—and the findings suggest that fish brains may, in some respects, be even more susceptible to antidepressants than human brains.

The research, led by Professor Shinichi Miyagawa of the Department of Biological Science and Technology at Tokyo University of Science and co-authored by Professor Masaru Ihara of Kochi University, tackles a long-standing gap in aquatic toxicology. Scientists have known for years that fish exposed to wastewater-contaminated water can exhibit altered behavior—changes in schooling, aggression, feeding, and reproduction. But observing a behavioral change tells you little about the mechanism producing it. Antidepressants primarily work by targeting proteins known as monoamine transporters, molecular pumps embedded in the membranes of neurons that sweep serotonin, dopamine, and norepinephrine back out of the synapse after a signal is fired. The three principal members of this family are the serotonin transporter (SERT), the dopamine transporter (DAT), and the norepinephrine transporter (NET). Block these transporters, and the chemical signals linger longer, amplifying mood-related signaling—which is exactly the therapeutic goal in humans, and potentially a profound disruption in fish.

Fish possess their own versions of these transporters, but whether those fish proteins respond to human-targeted pharmaceuticals in the same way as the human versions has remained largely unexplored. Compounding the uncertainty, most mechanistic work to date has focused on a narrow set of model species, leaving open the question of whether pharmaceutical sensitivity is a general feature of fish biology or a quirk of a few laboratory favorites. To answer this, the Japanese team cast a wider evolutionary net, selecting two species separated by substantial evolutionary distance: the medaka (Oryzias latipes), a small rice fish that is a staple of Asian molecular biology laboratories, and the ayu (Plecoglossus altivelis), a commercially and ecologically important migratory fish found in Japanese rivers and coastal waters. If two such distantly related species show similar drug sensitivities, the argument goes, the pattern is likely to hold across much of the fish tree of life.

The experimental approach was elegantly mechanistic. Rather than dosing whole animals and watching what happened, the researchers first identified and cloned the genes encoding DAT, NET, and—notably—two distinct forms of the serotonin transporter, labeled SERTa and SERTb, from both species. This genetic duplication of the serotonin transporter in fish, absent from mammals, immediately raised the question of which version, if either, responds to antidepressants. The team then expressed these cloned transporter genes in cultured human cells, producing the fish proteins in a controlled laboratory setting. By flooding these cells with a fluorescent marker that the transporters normally scoop up, and then adding antidepressants to the mix, the researchers could measure precisely how effectively each drug jammed each transporter: the more a drug inhibited uptake of the fluorescent probe, the more potent its interaction with that particular protein.

The first major revelation concerned the two serotonin transporter types. Across both species, SERTa proved consistently and dramatically more sensitive to antidepressants than SERTb. This asymmetry made evolutionary sense when the researchers examined the sequences. Human SERT belongs squarely to the SERTa lineage, while SERTb—the duplicated fish-specific copy—carries substitutions at several amino acid positions known to be critical for antidepressant binding. In other words, the duplicate copy that fish uniquely possess appears to have drifted away from the drug-binding architecture that pharmaceutical designers exploited when creating human medications. The fish transporter most similar to our own, SERTa, is the one that remains exquisitely drug-sensitive.

The second revelation was more surprising, and more troubling. When the team compared fish SERTa directly with human SERT, the fish transporter frequently responded to lower drug concentrations—sometimes requiring more than ten times less drug to achieve the same degree of inhibition. This means that at any given environmental concentration of an antidepressant, the molecular machinery governing serotonin signaling in a fish brain is likely to be affected more strongly than the corresponding machinery in a human. And the surprises did not stop there. Several drugs not classically regarded as acting on these transporter proteins in humans still bound to and inhibited the fish versions, hinting at pharmacological side effects in aquatic wildlife that could never have been predicted from human pharmacology textbooks alone.

Perhaps the most consequential finding is the one that bridges the laboratory and the real world. The concentrations of antidepressants needed to block medaka SERTa in these cell-based assays overlapped directly with concentrations already measured in polluted waterways. Duloxetine, fluoxetine, citalopram, and paroxetine—all heavily prescribed medications—inhibited the medaka serotonin transporter at concentrations ranging from a few hundred nanograms per liter up to roughly 1,300 nanograms per liter, figures that sit squarely within the range documented in contaminated rivers and effluent-affected waters around the world. This is not a case of a laboratory effect requiring doses orders of magnitude above environmental relevance. The molecular target and the environmental exposure exist in the same quantitative universe.

“By demonstrating that key molecular targets in fish can be more sensitive than their human equivalents, our work offers crucial insights into the potential risks of pharmaceutical exposure to aquatic wildlife,” Professor Miyagawa noted. The implications ripple outward from molecular pharmacology into ecology. Serotonin signaling in fish influences a wide array of behaviors, including foraging, predator avoidance, shoaling, and reproductive courtship. Chronic inhibition of serotonin reuptake at environmentally realistic concentrations could, in principle, subtly rewire these behaviors across entire populations, with downstream consequences for survival and reproduction that laboratory assays of transporter inhibition cannot yet capture.

This is precisely where the study’s choice of species strengthens its message. Because medaka and ayu occupy distant branches of the fish evolutionary tree, yet display a shared pattern of heightened transporter sensitivity, the researchers argue that this vulnerability is unlikely to be a species-specific anomaly. The pharmacological architecture of the fish monoamine system—the drug-sensitive SERTa lineage, in particular—appears to be a shared ancestral trait, meaning that salmon, carp, trout, and countless other species may carry similarly sensitive molecular targets swimming through their synapses.

The research also carries a direct message for regulators and water quality authorities. Environmental monitoring programs currently face an impossible task: tracking thousands of pharmaceuticals with limited resources. Molecular sensitivity data of the kind generated by Miyagawa and Ihara’s team offers a rational basis for triage, allowing regulators to prioritize the compounds most likely to cause harm at environmentally relevant concentrations. “Our research provides a vital scientific basis for prioritizing specific pharmaceuticals in environmental monitoring programs and for deriving more protective, species-specific risk thresholds in water quality guidelines,” Miyagawa explained. In other words, safety thresholds derived from human pharmacology—or even from a single fish model—may systematically underestimate risk for the broader aquatic community.

Important questions remain. The present work was conducted in engineered human cells expressing fish transporters, a powerful system for isolating molecular interactions but one that strips away the complexity of a living animal—metabolism, blood-brain barriers, mixtures of co-occurring drugs, and compensatory physiological responses. The authors themselves emphasize that future in vivo studies examining environmentally realistic exposure scenarios and realistic pharmaceutical cocktails will be essential to determine how these molecular effects translate into measurable biological and ecological outcomes. Still, the study delivers a clear and sobering headline: the molecular locks that antidepressants were built to pick exist in fish brains too, and in fish, at least some of those locks turn more easily. As global antidepressant use continues to climb, the invisible pharmacological fingerprint of human medicine is being written into the neurochemistry of the animals that share our water—and their brains, this research suggests, may be reading that fingerprint more clearly than we ever imagined.